This meeting is sponsored by UCB.CME accreditation applied for.Date of Preparation: October 2012Code: IMNL-SCT-016659-102012 © UCB S.A. 2012. All rights reserved.

You will have the opportunity to attend up to four `mini-symposia’ sessions. A selection of the mini-symposia available is provided below. A full list of available sessions and information on how to pre-register will be provided.

Len Calabrese Managing Comorbidities in Rheumatologic Diseases

Tom Huizinga Predicting Clinical Response – Biomarkers and Genetics

Georgy Nagy Clinical Cases – Management of the Difficult RA patient

Claire Bombardier Quality Indicators in RA

Roy Fleischmann Oral Therapies – Clinical Data

Walter GrassiFred Joshua

To Be or Not to Be in Remission: Can Ultrasound Guide Us?

Annelies BoonenLaure Gossec

Patient Reported Outcomes: Can Patients Tell Us More?

Maxime DougadosFilip Van den Bosch

Update in Spondyloarthropathies

Robert LandewéXenofon Baraliakos

AxSpA: Interpretation of Imaging (X-ray, MRI)

Astrid van Tubergen Epidemiology of Axial SpA

Fred Houssiau Updates in the Management of Renal Disease in SLE

Speaker TBC Cardiovascular Risk Management in SLE

Speaker TBC Family Planning in SLE

Thomas Dörner Treatment Goals and Disease Activity Assessment in SLE

Georg Schett Osteoimmunology

Rik LoriesPiet Geusens

Bone Biology and Novel Osteoporosis Agents

Stephen HallNicolò Pipitone

Managing Vasculitis

Dominique Baeten Updates in Basic Immunology

Athol Wells Interstitial Lung Disease

Mini-Symposium

THE FOURTH INTERNATIONAL IMMUNOLOGY SUMMITClinical Implications of Scientific Breakthroughs in Immune-Mediated Diseases

21st to 23rd February 2013, Prague, Czech RepublicChaired by Peter Nash

CME accreditation applied for

On behalf of myself and our faculty of distinguished specialists I am delighted to invite you to join us at the Fourth International Immunology Summit.

Within the fi eld of immunology, analogous to the challenge of climbing a mountain, we have faced a steep climb in the treatment of our patients. Our initial goals of symptom control and disease modifi cation have been surpassed in many cases, and we continue to advance up the treatment pyramid as our focus increasingly shifts to remission and drug-free remission. This meeting will consider the scientifi c data and clinical guidance that can help us to continue this advance, and will close with discussions of our hopes for the future, of reaching the peak of management through the cure, and ultimately prevention of immunological conditions.

This meeting will review the latest scientifi c developments across immune-mediated diseases and consider how these novel updates can be implemented in the clinic to improve the care of our patients. The programme will cover a wide range of relevant topics including:• New pathways and targets in immunology• Managing comorbidities in rheumatologic diseases• Scientifi c approaches to early aggressive treatment in RA and translation of clinical

trial data into daily practice• Pathogenesis of axial SpA and PsA and novel management approaches• Future developments in rheumatic disease imaging • Novel pathways and therapies in SLE • Novel pathways and therapies in osteoporosis

The Summit will provide the opportunity for discussion, interaction, networking and debate with many leading experts in their respective fi elds.

The meeting will start at 11am on the morning of Thursday 21st February and fi nish at lunchtime on Saturday 23rd February. In addition to the main plenary sessions you will have the opportunity to attend up to four highly interactive ‘mini-symposia’ sessions, providing the opportunity to consider the most novel developments across a wide range of topics most relevant to the management of our patients.

I very much look forward to welcoming you to what promises to be a highly exciting, interactive and enjoyable meeting.

Kind regards

Peter Nash MBBS (hons) FRACP (Course Director)Associate Professor, Department of Medicine, University of QueenslandDirector of the Rheumatology Research Unit, Sunshine Coast, Australia

Thursday 21st February 2013

1000 – 1100 Arrivals and Coffee

1100 – 1110 Welcome and Introduction from the Course Director Peter Nash (Australia)

Updates in Immunology

1110 – 1140 New Pathways and Targets in Immunology Dominique Baeten (NL)

1140 – 1210 Introduction of Novel Agents – Implications for Clinical Practice

Peter Taylor

1210 – 1220 Questions and Answer Session

1220 – 1330 Lunch

Management of Rheumatological Diseases

1330 – 1400 Managing Comorbidities in Rheumatologic Diseases Len Calabrese (US)

1400 – 1430 Family Planning and Pregnancy in Immunological Disease

Speaker to be confi rmed

1430 – 1500 Advances in Interstitial Lung Disease – Classifi cation, Investigation & Management

Athol Wells (UK)

1500 – 1515 Questions and Answer Session

1515 – 1545 Coffee

Rheumatoid Arthritis

1545 – 1615 Biologic Agents – An Update of Safety Data Xavier Mariette (France)

1615 – 1645 Early and Aggressive Management of RA Speaker to be confi rmed

1645 – 1715 Translating Trial Data into Clinical Practice Josef Smolen (Austria)

1715 – 1730 Questions and Answer Session

1730 – 1900 Mini-Symposium Session 1

2000 Buffet Dinner

Friday 22nd February 2013

axSpA and PsA

0830 – 0900 Pathogenesis and Novel Targets in PsA Chris Ritchlin (US)

0900 – 0930 Update on Trials and Novel Therapies in PsA Doug Veale (Ireland)

0930 – 0940 Questions and Answer Session

ProgrammeDear Colleagues and Friends,

0940 – 1010 Coffee

1010 – 1040 Axial SpA – Pathogenesis and Burden of Disease Désirée van der Heijde (NL)

1040 – 1110 Update on Trials and Novel Therapies in SpA Filip van den Bosch (Belgium)

1110 – 1120 Questions and Answer Session

1120 – 1250 Mini-Symposium Session 2

1250 – 1420 Lunch

1420 – 1500 Future Developments in Rheumatic Disease Imaging Robert Landewé (NL)

SLE

1500 – 1530 Basic Science – Pathogenesis of SLE Thomas Dörner (Germany)

1530 – 1600 Novel Therapies in SLE Joan Merrill (USA)

1600 – 1615 Questions and Answer Session

1615 – 1645 Coffee

1645 – 1815 Mini-Symposium Session 3

2000 Summit Dinner

Saturday 23rd February 2013

0830 – 1000 Mini-Symposium Session 4

1000 – 1030 Coffee

Bone Biology

1030 – 1100 Updates in Osteoporosis Eugene McCloskey (UK)

1100 – 1130 Novel Pathways in Osteoporosis Christian Roux (France)

1130 – 1140 Questions and Answer Session

1140 – 1210 Reaching the Summit – The Future of Immunological Disease Management

Speaker to be confi rmed

1210 – 1230 Meeting Summary and Close

1230 – 1330 Lunch

Programme may be subject to minor changes